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Abstract
Background: Deletion or mutation(s) of the survival motor neuron 1 (SMN1) gene causes spinal muscular atrophy
(SMA), a neuromuscular disease characterized by spinal motor neuron death and muscle paralysis. Complete loss of
the SMN protein is embryonically lethal, yet reduced levels of this protein result in selective death of motor
neurons. Why motor neurons are specifically targeted by SMN deficiency remains to be determined. In this study,
embryonic stem (ES) cells derived from a severe SMA mouse model were differentiated into motor neurons in vitro
by addition of retinoic acid and sonic hedgehog agonist. Proteomic and western blot analyses were used to probe
protein expression alterations in this cell-culture model of SMA that could be relevant to the disease.
Results: When ES cells were primed with Noggin/fibroblast growth factors (bFGF and FGF-8) in a more robust
neural differentiation medium for 2 days before differentiation induction, the efficiency of in vitro motor neuron
differentiation was improved from ~25% to ~50%. The differentiated ES cells expressed a pan-neuronal marker
(neurofilament) and motor neuron markers (Hb9, Islet-1, and ChAT). Even though SMN-deficient ES cells had
marked reduced levels of SMN (~20% of that in control ES cells), the morphology and differentiation efficiency for
these cells are comparable to those for control samples. However, proteomics in conjunction with western blot
analyses revealed 6 down-regulated and 14 up-regulated proteins with most of them involved in energy
metabolism, cell stress-response, protein degradation, and cytoskeleton stability. Some of these activated cellular
pathways showed specificity for either undifferentiated or differentiated cells. Increased p21 protein expression
indicated that SMA ES cells were responding to cellular stress. Up-regulation of p21 was confirmed in spinal cord
tissues from the same SMA mouse model from which the ES cells were derived.
Conclusion: SMN-deficient ES cells provide a cell-culture model for SMA. SMN deficiency activates cellular stress
pathways, causing a dysregulation of energy metabolism, protein degradation, and cytoskeleton stability.
Background
Spinal muscular atrophy (SMA) is an autosomal reces-
s i v ed i s o r d e rw i t hap r e v a l e n c eo f1i n6 0 0 0l i v eb i r t h s
and a carrier incidence of 1 in 40-50 [1,2]. The hallmark
of SMA is death of spinal motor neurons and progres-
sive muscle atrophy [3]. Based on age of onset and clini-
cal severity, childhood SMA has been classified into
types I, II, and III [2,4]. Type I SMA is the most severe,
resulting in the death of the child before the age of two,
while type II and III individuals can live on into
adulthood; however, they suffer from varying degrees of
muscle paralysis and atrophy.
Genetic analyses of familial SMA indicate that the vast
majority of SMA is caused by deletion or mutation(s) of
the telomeric copy of the survival motor neuron 1
(SMN1)g e n e[ 5 ] .C o m p l e t el o s so ft h i sg e n ei na l ls p e -
cies is lethal. In humans, a highly homologous centro-
meric copy of the SMN gene, SMN2, enables patient
survival, but it cannot completely compensate for the
loss of SMN1 [6,7]. The encoded SMN protein has been
shown to play an essential role in the assembly of small
nuclear ribonucleoprotein (snRNP) complexes [8-10].
SMN appears to function in snRNP biogenesis by inter-
acting with Gemins 2-8, and Unrip [8,11,12]. A correla-
tion between snRNP assembly activity in the spinal cord
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demonstrated [13]. Widespread pre-mRNA splicing
defects have also been seen in many cells and tissues in
an SMA mouse model, indicating that SMA may be a
general splicing disorder [14].
Reduced levels of SMN in SMA patients and animal
models result in selective death of motor neurons, indi-
cating that SMN plays a more critical role in motor
neurons. Consistent with this indication, SMN has been
shown to localize to granules that are actively trans-
ported into neurites and growth cones [15]. Axonal
SMN appears to associate with heterogenous nuclear
ribonucleoprotein R (hnRNP R) and to be involved in
the transport of b-actin mRNA [16]. Indeed, distal
axons and growth cones of motor neurons from SMA
mice have defects in neurite outgrowth and reduced
levels of b-actin mRNA and protein [16]. Zebra fish
motor neurons with SMN deficiency also exhibit shorter
and/or abnormally branched axons [17,18]. Recent stu-
dies in SMA mouse models further identified pre-synap-
tic defects including poor arborization, intermediate
filament aggregation, impaired synaptic vesicle release,
and trunk denervation [19-24]. Collectively, these data
support a specific function for SMN in motor neurons
and neuromuscular junctions.
Several SMA mouse models have been developed in
the past decade [24-27]. One severe SMA mouse model
(SMN2
+/+Smn
-/-) most closely mimics human type I
S M Ai nt h a ti tl a c k st h em o u s eSmn gene but carries
two copies of the human SMN2 gene [25]. The SMA
pups with this genotype appear normal at birth, but at
post-natal day 2 (P2), they develop SMA-like symptoms
including reduced suckling, decreased movement, and
labored breathing. The pups die by P6-7. The short life-
span in this SMA mouse prohibits wide use of this
model for mechanistic studies or drug development for
SMA. Thus, development of an in vitro cell-culture sys-
tem from this transgenic mouse, that recapitulates
motor neuron differentiation and the unique features of
mature motor neurons such as extension of axons and
formation of neuromuscular junctions, will enable us to
study motor neuron-specific functions of SMN.
Embryonic stem (ES) cells are unique cells derived
from the inner cell mass of the mammalian blastocyst.
These cells are pluripotent, immortal, and can be differ-
entiated into mature cell types in response to specific
cues [28,29]. Generation of spinal neurons can be
achieved by exposure of embryoid bodies (EBs) to reti-
noic acid (RA) and sonic hedgehog (Shh) or a hedgehog
agonist [30,31]. Motor neurons differentiated via this
protocol were found to extend axons and form synapses
with target muscle when implanted in the spinal cord
[31-34], thus confirming the power of this approach in
generating mature neuronal subpopulations.
In this study, we report on the effects of the differen-
tiation of ES cells derived from the severe SMA mouse
model into motor neurons. We developed a new proto-
col to improve differentiation efficiency from ~25% to
~50%. The differentiated motor neurons were character-
ized by immunofluorescence and western blotting of
neuronal and motor neuron markers. Using proteomic
techniques, we determined that multiple signaling path-
ways are dysregulated in SMA cells.
Results
In vitro motor neuron differentiation is enhanced by
increasing neural patterning with Noggin and fibroblast
growth factors
To establish a cell-culture model of SMA, we initially
used the control ES line (HBG3; HB9::eGFP) to optimize
in vitro conditions for differentiation of ES cells into
motor neurons. Since HBG3 ES cells were derived from
a transgenic mouse expressing eGFP under the control
of motor neuron specific promoter Hb9 [31], the effi-
ciency of differentiation can be monitored by measuring
the population of GFP
+ cells. Initially, ES cells were pro-
pagated on mouse embryonic fibroblasts and differen-
tiated by the addition of RA and a Shh agonist
(smoothened agonist, SAG) using a previous published
protocol [31]. Retinoic acid caudalizes neural progeni-
tors, while Shh has a ventralizing effect, leading to dif-
ferentiation into motor neurons [31]. We optimized
concentrations of RA (0.001-2 μM) and SAG (0.001-1
μM) and found that a combination of 1 μMR Aa n d1
μM SAG gave the best degree of differentiation (~25%).
Purmorphamine, a compound that activates the hedge-
hog signaling pathway and directs motor neuron differ-
entiation [35,36], was also tested at 1-2.5 μM
concentrations in combination with 1 μMR A ,b u tt h e
differentiation rate was always less than 20%. In order to
enhance the neuralization process, we primed the ES
cells with the bone morphogenetic protein antagonist,
Noggin, and with bFGF and FGF-8 (see Methods) prior
to the 5-day induction period with RA and SAG (Figure
1A). Noggin is implicated in neural induction according
to the default model of neurogenesis and results in the
formation of anterior neural patterning, while FGF acts
synergistically with Noggin in inducing neural tissue for-
mation by promoting a posterior neural identity [37-40].
Priming ES cells with these two signaling molecules
before differentiation induction significantly increased
GFP
+ population from 24.8% ± 8.1 to 51% ± 0.8% (n =
3; p <0 . 0 1 ,S t u d e n t ’s t-test). The differentiated ES cells
extend long processes when plated on poly-ornithine/
laminin/matrigel-coated dishes (Figure 1).
The differentiated cells were characterized by the
expression of neuronal and motor neuron marker pro-
teins. Western blotting shows that a pan-neuronal
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Page 2 of 13marker (neurofilament) and two motor neuron specific
markers (Hb9 and ChAT) are expressed in differentiated
ES cells but not in the undifferentiated ES cells (Figure
2A). Immunofluorescence staining shows that differen-
tiated motor neurons are neurofilament, ChAT, and
Islet-1 positive (Figure 2B).
Proteomic analyses reveal altered protein expression in
SMN-deficient ES cells
The SMA ES cells were derived from a severe SMA
transgenic mouse that lacks the murine Smn gene but
carries two copies of the human SMN2 gene [25]. Wes-
tern blotting shows that SMA ES cells have a marked
r e d u c t i o ni nS M Np r o t e i n( ~ 2 0 %o fc o n t r o l ,F i g u r e3 ) .
The SMN-interacting protein Gemin2 was also
significantly decreased (~40-50% of control, Figure 3).
However, morphologically, SMA ES cells did not differ
from the control ES cells (data not shown). Under the
optimized differentiation conditions, SMN-deficient ES
cells were differentiated into motor neurons in vitro as
evidenced by neurofilament, ChAT, and Hb9 expression
(Figure 4A). Despite a drastic difference in SMN levels
(Figure 3), control and SMA ES cells showed similar
levels of neuronal and motor neuron marker expression
after differentiation (Figure 4B). This is consistent with
immunostaining results showing that 45-50% of differen-
tiated cells were Hb9
+ in both control and SMA ES cells.
To identify proteins that are up- or down-regulated in
SMN-deficient ES cells, comparative two-dimensional
SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
Figure 1 Differentiation of murine ES cells into motor neurons. The scheme outlines the process of motor neuron differentiation from ES
cells (A). Murine ES cells (HBG3) were expanded on a layer of primary mouse embryonic fibroblasts. Undifferentiated stem cells form round
clusters (arrows) as they proliferate on top of a feeding fibroblast layer, and they have weak GFP expression (B-B’). Stem cells were separated
from the fibroblast layer and plated in low attachment dishes to allow for differentiation. Two-day-old stem cell aggregates (called embryoid
bodies, EB, arrows) were induced to differentiate with 1 μM retinoic acid and 1 μM sonic hedgehog agonist SAG for 5 days. Differentiated ES
cells have strong GFP expression (C-C’). When plated on poly-DL-ornithine/laminin/matrigel coated plates, the differentiated ES cells extend long
neurites after 2 days in culture (D-D’). Representative phase contrast images for 1B-1D are shown on the top and corresponding fluorescent
images are on the bottom. Scale bar = 200 μm except as indicated. MN = motor neuron.
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Page 3 of 13Figure 2 Characterization of motor neuron differentiation. HBG3 cells were induced to differentiate following the procedure as in 1A.
Lysates from undifferentiated and differentiated cells were resolved on an SDS-PAGE and transferred to a membrane. The blot was probed with
antibodies against pan-neuronal (neurofilament, NF) and motor neuron markers (Hb9 and ChAT). The same blot was stripped and re-probed
with anti-ERK antibodies for protein loading control (A). Differentiated ES cells were dissociated and processed for indirect immunofluorescence
staining for neurofilament (NF, in red), ChAT (in red), Islet-1 (in red), and DAPI (for nuclei in blue). Scale bar = 50 μm. U = undifferentiated cells
and D = differentiated cells.
Figure 3 Reduced expressions of SMN and Gemin2 in SMN-
deficient ES cells. Control (C) and SMA (S) ES cells were separated
from feeding fibroblasts and allowed to differentiate in vitro in the
presence of RA and SAG for 5 days. Both undifferentiated and
differentiated cells were harvested and lysates were prepared. Equal
amounts of total proteins were separated by SDS-PAGE, and SMN
and Gemin2 were detected by western blotting. The same blot was
stripped and re-probed with ERK antibodies for protein loading
control (A). Signals were quantified, relative ratios of SMN or
Gemin2 to ERK were calculated, and the mean value ± SD of three
independent experiments is presented here. Statistical analyses
(Student’s t test) indicate that SMA cells have significantly reduced
levels of SMN and Gemin2 expression (approximately 20% of the
control for SMN and 40-50% for Gemin2) (** p < 0.01 and * p <
0.05) (B). Undiff. = undifferentiated cells and Diff. = differentiated
cells.
Figure 4 Characterization of differentiation of control and
SMN-deficient ES cells. Control (C) and SMA (S) ES cells as
described in 3A were processed for western blotting using
antibodies against neurofilament (NF), Hb9, and ChAT respectively.
The same blot was stripped and re-probed with anti-ERK antibody
for protein loading control (A). Signals of three independent
experiments were quantified, normalized to ERK, and plotted as for
3B. Differentiated control and SMA ES cells show similar levels of
expression for neuronal and motor neuron marker proteins (B).
Undiff. = undifferentiated cells and Diff. = differentiated cells.
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The differences between control and SMN-depleted pro-
tein pools were analyzed using four separate control and
SMA ES cell extracts and quantified using DeCyder soft-
ware (Figure 5). A total of 1900 spots were identified.
Spots that differed with a p-value less than 0.05 (t-test)
and that showed an average ratio of expression greater
than or less than 1.5 were marked as points of interest
(POI). For the undifferentiated ES cell samples, the 11
most abundant of the total 34 POIs were picked, and
for the differentiated ES cell samples, the 14 most abun-
dant of the total 32 POIs were picked. The protein iden-
tities of the picked POIs were determined by trypsin
digestion and mass spectrometry. The majority of
detected proteins were expressed at similar levels in
control and SMA ES cells (Figure 5), but in our proteo-
mic analyses, we were able to identify 4 out of 11 pro-
teins in the undifferentiated samples and 11 out of 14
proteins in the differentiated samples that were signifi-
cantly altered in SMA ES cells (Table 1). Most of the
proteins identified as differentially expressed in SMA ES
cells are involved in stress-responses (peroxiredoxin,
stress induced phophoprotein, and chaperone proteins),
cell metabolism (lactate dehydrogenase, glyoxalase 1,
brain creatine kinase, and aldehyde dehydrogenase), pro-
tein turnover and ubiquitin modification (ubiquitin
C-terminal hydrolase L1), and cytoskeleton stability (a-
tubulin and tropomyosin 3). Consistent with our finding,
ubiquitin C-terminal hydrolase L1 is up-regulated in
type I SMA fibroblasts [41], and tropomyosin 3 is up-
regulated while peroxiredox i ni sd o w n - r e g u l a t e di nt h e
hippocampus of Smn-/-; SMN2+/+ mice [42]. We
obtained antibodies to six of the differentially expressed
proteins to validate the proteomic results. Western blot
analysis confirmed that expression of peroxiredoxin 6 is
increased in undifferentiated SMA cells and that lactate
dehydrogenase and tropomyosin 3 are increased in dif-
ferentiated SMA ES cells (Figure 6). However, no signifi-
cant changes in levels of heat shock proteins 70/90 or
tubulin were detected by western blotting (Figure 7).
Western blotting showed that expression of lactate
dehydrogenase was increased in both undifferentiated
and differentiated SMA ES cells, indicating increased
metabolic activity in SMN-deficient cells.
Western blot analysis reveals specific cell stress-response
pathways activated in SMN-deficient ES cells
Our proteomic study indicates that reduced levels of SMN
increase expression of stress-response proteins (Table 1).
Specific stress-response pathways dysregulated in SMN-
deficient ES cells were analyzed by western blotting. We
first analyzed levels of the stress-activated protein kinase/
Figure 5 Comparative 2D DIGE analysis of protein expression in control and SMA ES cells. Control and SMA ES cells were harvested and
lysed. Equal amounts of total proteins from wild-type or SMA ES cells were trace labeled with either Cy3 or Cy5. The dyed proteins indicated by
the labeled colors were mixed and separated by isoelectric focusing in 7 cm pH 3-10 linear gradient IPG strips, and further separated in a
second dimension of 10% SDS-PAGE. Fluorescently labeled proteins were visualized by Typhoon Trio scanner and difference between samples
analyzed by the accompanied software. Samples shown in the left and right panels were from different preparations of ES cells and labeled with
opposite dyes to demonstrate the reproducibility of the assay. A few abnormally expressed corresponding proteins were marked by arrows. MW
= molecular weight.
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kinase in SMN-deficient ES cells. JNK and p38 MAP
kinase are the two major stress-response pathways that are
activated by a variety of cellular stresses including UV light
and growth factors [43,44]. Levels of phosphorylated p38
were elevated in SMA ES cells (~2.8 fold increase for the
undifferentiated cells and ~1.7-fold increase for differen-
tiated cells; Figure 8). Levels of phosphorylated JNK were
also increased in both undifferentiated (~6.4 fold) and dif-
ferentiated (~1.3 fold) SMA ES cells when compared to
control ES cells. Up-regulation of phosphorylated JNK was
previously seen in primary muscle cultures derived from
SMA patients, although total levels of this protein were
reduced in these cells [45]. Another cell stress-response
protein that is often found in stress granules where SMN
is seen to localize [46,47], TIA-1, was also up-regulated in
SMA ES cells (~2 fold for undifferentiated cells and ~1.5
folds for differentiated cells). Activated in response to FAS
ligand stimulation, TIA-1 appears to function as a media-
tor of apoptotic cell death [48]. Protein disulfide isomerase
was down-regulated in SMA ES cells, but the vast majority
of chaperones and ER stress-related proteins were not
changed (Figure 7). Levels of p53, Bax, Bad, and Puma
were also not affected in SMA ES cells (Figure 9).
Cellular stress-response protein p21 is up-regulated in
both SMN-deficient ES cells and in spinal cords of SMA
transgenic mice
The tumor suppressor protein p21 Waf1/Cip1 acts as
an inhibitor of cell-cycle progression. It has been shown
that p21 is induced in response to a variety of stress
signals, including genotoxins, oxidants, and metabolic
perturbation [49]. Western blot analyses show that
levels of p21 are increased in both undifferentiated
and differentiated SMA ES cells (Figure 10A). In differ-
entiated control cells, p21 is expressed at very low levels
but is increased by as much as 41.7 ± 0.3 fold (n = 4
independent experiments, p < 0.05, Student’s t-test) in
differentiated SMA cells. By contrast, the expression of
another member of the Cip/Kip family of cyclin-depen-
dent kinase inhibitors, p27, was unaffected (Figure 10A).
p21 is also up-regulated in spinal tissue obtained from
S M At r a n s g e n i cm i c ec o m p a r e dt os p i n a lt i s s u ef r o m
c o n t r o lm i c e( 1 7 . 1±0 . 2f o l d ,p < 0.01, Student’s t-test,
Figure 10B).
Discussion
In this study, we have developed an improved protocol
for in vitro motor neuron differentiation using GFP
expression as a readout in the control ES line (HBG3,
HB9::eGFP) [31]. This protocol employs a multi-step
process that involves priming ES cells with Noggin and
FGFs prior to addition of signaling molecules RA and
SAG (Figure 1). Using this modified procedure, we were
able to generate a motor neuron population in vitro
with high efficiency (~50%). The differentiated ES cells
acquired immunohistochemical features of motor neu-
rons as evidenced by expression of neuronal and motor
neuron markers (Figure 2). We also derived ES cells
from a severe transgenic SMA mouse for differentiation
to provide a cell-culture model for type I SMA. Apply-
ing this method to SMA ES cells, we were able to
Table 1 Proteomic identification of dysregulated proteins in SMN-deficient ES cells
Protein Name Gene Symbol Fold Change Function
Undifferentiated
Chaperonin 6a Cct6a +2.6 Protein folding
FK506 binding protein 4 Fkbp4 +1.75 Protein folding and trafficking
Peroxiredoxin 6 Prdx1 +1.6 Redox regulation
Stress-induced-phosphoprotein 1 Stip1 -1.75 Adaptor protein for Hsp70 and Hsp90
Differentiated
Lactate dehydrogenase B Ldhb +3.6 Glycolysis
Brain creatine kinase Ckb +1.8 Cellular energy homeostasis
Glyoxalase 1 Glo1 +1.75 Detoxification of glucose degradation products
Tropomyosin 3 Tpm3 +1.75 Stabilization of actin filaments
Annexin A5 Anxa5 +1.7 Cell signaling, Inflammation; Growth/differentiation
Ubiquitin carboxy-terminal hydrolase L1 Uchl1 +1.7 De-ubiquitination; Ubiquitin ligation; Mono-ubiquitin stabilizer
Alpha-tubulin Tuba1a +1.5 Cytoskeletal protein
Aldehyde dehydrogenase Aldh5a1 -1.7 Aldehyde oxidation
14-3-3 gamma Ywhag -1.7 Cell signaling; Check point control; Apoptosis
Heat shock protein 90B Hsp90b1 -1.8 Chaperone protein
Heat shock protein 70K Hspa9 -2.2 Chaperone protein; Cell proliferation
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Page 6 of 13perform proteomic analyses to identify pathways
affected in both undifferentiated and differentiated SMA
ES cells.
Differentiation efficiency of control and SMA ES cells
were similar, but our study shows that several pathways
involved in cell stress-response, energy metabolism, pro-
tein turnover, and cytoskeleton stability are affected by
low expression of SMN (Table 1). Interestingly, similar
disturbances in these pathways have been reported in
other proteomic studies using different proteomic
approaches that were conducted in SMN-deficient cells
and tissues other than motor neurons [41,42,45,50,51].
Although motor neurons are the primary cells affected
in SMA, most studies use alternative tissues or cell cul-
tures because of difficulties in obtaining motor neurons
from affected animals. Antibodies detect proteins with
higher specificity and sensitivity, but such studies are
restricted by availability of suitable antibodies for blotting
or antibody arrays. By comparison, comparative two-
dimensional SDS-PAGE difference gel electrophoresis and
iTRAQ analyses can be used to provide unbiased analysis
of protein changes. For iTRAQ expression, differences are
determined from alterations in quantities of the tags used
to label discrete populations of peptides derived from pro-
teins isolated from control and affected cells or tissues.
This requires all peptides to be identified by LC/MS/MS.
For gel systems, differences in quantities of dye-tagged
proteins are determined, and only differentially expressed
proteins need to be processed for identification by MS/
MS. We detected 1900 spots using two-dimensional SDS-
PAGE compared to an iTRAQ study with SMA fibroblasts
that detected 2171 proteins [50]. In both techniques,
quantification of less-abundant proteins is less accurate.
Among dysregulated proteins that are involved in cellular
metabolism, we confirmed up-regulation of lactate dehy-
drogenase in SMA ES cells by western blotting (Figure 6).
Lactate dehydrogenase is an oxidoreductase of the glycoly-
sis pathway that catalyses the interconversion of pyruvate
and lactate with concomitant interconversion of NADH
and NAD+ [52]. Aberrant expression of lactate dehydro-
genase and other energy metabolism enzymes (e.g., glyoxa-
lase 1, brain creatine kinase, aldehyde dehydrogenase) in
SMA cells could disturb energy production and consump-
tion, and contribute to the pathology of SMA. Consistent
with our findings, mRNAs encoding several enzymes of
glycolysis are aberrantly expressed in muscles derived
from SMA patients [53].
In our proteomic analyses, we also found up-regula-
tion of tropomyosin in differentiated SMA ES cells
Figure 6 Abnormal expression of peroxiredoxin 6, tropomyosin,
and lactate dehydrogenase in SMN-deficient ES cells. Control (C)
and SMA (S) ES cells as described in 3A were processed for western
blotting using antibodies against peroxiredoxin 6 (PRDX6),
tropomyosin (TPM1/3), and lactate dehydrogenase (LDH),
respectively. The same blot was stripped and re-probed with anti-ERK
antibody for protein loading control (A). Signals of three
independent experiments were quantified, normalized to ERK, and
plotted as for 3B. Western blotting confirms that SMA ES cells show
significantly higher levels of peroxiredoxin 6, tropomyosin, and
lactate dehydrogenase expression (** p < 0.01 and * p < 0.05) (B).
Undiff. = undifferentiated cells and Diff. = differentiated cells.
Figure 7 Western blotting profile of a-tubulin and chaperone-
related proteins. Control (C) and SMA (S) ES cells as described in
3A were processed for western blot analyses using antibodies
against a-tubulin, chaperone-related proteins as indicated, and
protein loading control ERK. Undiff. = undifferentiated cells and Diff.
= differentiated cells.
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Page 7 of 13(Table 1, Figure 6). A similar finding was reported in
the hippocampus of Smn-/-; SMN2+/+ mice [42]. Tro-
pomyosin is a dimeric coiled-coil protein that binds
along the length of actin filaments. In non-muscle
cells, tropomyosin stabilizes cytoskeleton actin fila-
ments [54]. Thus, dysregulation of tropomyosin could
compromise actin dynamics and cytoskeleton stability.
Levels of other actin binding proteins have been pro-
posed to play a role in SMA. Profilin II, the small
actin-binding protein that associates with SMN [55,56],
is up-regulated in both SMN-depleted PC12 cells and
cells from an SMA mouse model [57,58]. The actin
bundling protein Plastin 3 has recently been identified
as a protective, gender-specific modifier of SMA and is
associated with SMN and actin in a large protein com-
plex [59]. Together, these findings implicate a role for
disruption of actin cytoskeletal dynamics in SMA
pathogenesis.
Up-regulation of peroxiredoxin 6 in SMA ES cells
(Table 1 and Figure 6), and increased expression of per-
oxiredoxin protein in SMA mouse tissue [42], implicates
cell stress-responses in SMA. Peroxiredoxin 6 is an anti-
oxidant enzyme that reduces levels of H2O2 to protect
cells from oxidative injury [60]. Up-regulation of perox-
iredoxin 6 could be a compensatory response to poten-
tially increased oxidative stress in SMN-deficient cells.
Reduced levels of SMN have been shown to cause mito-
chondrial dysfunction [61], which can initiate oxidative
stress. Expression of peroxiredoxin 6 is also increased in
am u t a n tS O D 1m o u s em o d e lo fa m y o t r o p h i cl a t e r a l
sclerosis [62]. Interestingly, over-expression of SMN
protects cells against cell death induced by mutant
SOD1 under oxidative stress [63]. To investigate the
notion that SMN deficiency might lead cells in stress in
more detail, we used western blotting to show that acti-
vation of the p38 MAP kinase and JNK pathways were
increased in both undifferentiated and differentiated
Figure 8 Elevated expressions of stress-related proteins in SMN-deficient ES cells. Control (C) and SMA (S) ES cells as described in 3A were
processed for western blotting using antibodies against phosphorylated p38 (pP38), p38, phosphorylated JNK (p-JNK), JNK, and TIA-1. The same
membranes were stripped and re-probed with anti-ERK antibody for protein loading control (A). Signals of three independent experiments were
quantified, normalized to corresponding ERK signals, and plotted as for 3B. SMA ES cells express significantly higher levels of phosphorylated
p38, phosphorylated JNK, and TIA-1 proteins (** p < 0.01 and * p < 0.05) (B). Undiff. = undifferentiated cells and Diff. = differentiated cells.
Figure 9 Western blotting profile of cell death-related proteins.
Control (C) and SMA (S) ES cells as described in 3A were processed
for western blot analyses using antibodies against Bax, Bad, Puma,
p53, and protein loading control ERK. Undiff. = undifferentiated cells
and Diff. = differentiated cells.
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Page 8 of 13SMA ES cells (Figure 8). Both of these pathways have
been implicated in neuronal cell death by activating
apoptotic pathways in response to heat and osmotic
shock, genotoxic damage, X-ray and UV radiation, and
proinflammatory cytokines [64,65]. We also showed that
the stress-response protein TIA-1 is increased in SMA
ES cells (Figure 8). TIA-1 is often localized in stress
granules where SMN is seen to locate [47]. Notably,
expression of the stress-response protein p21 is
increased significantly in both SMA ES cells and spinal
cord tissues of a mouse model of SMA (Figure 10). We
could not determine whether disease progression affects
p21 expression because we were unable to recover suffi-
cient spinal cord samples from different aged SMA
mice. Although p21 expression is higher in undifferen-
tiated SMA cells than in undifferentiated control cells,
the differences are much more striking in the differen-
tiated cells. Up-regulation of p21 is a cellular response
to stress that leads to cell growth arrest and favors cell
survival [66], but prolonged stress in SMA cells will
eventually lead to cell death. Transcription factors such
as p53, Sp1, p300, CEBPb, and Stats induce expression
of the p21 gene [49,67]. However, as p53 levels are not
altered in SMN-deficient cells (Figure 9), it is unlikely
that up-regulation of p21 is mediated by this transcrip-
tion factor in SMN-deficient cells. Thus, the mechanism
by which SMN deficiency leads to up-regulation of p21
is not yet clear.
Our analyses show a number of pathways that are dys-
regulated in SMA ES cells but the most important may
be induction of cell stress. This cell stress might explain
why we see significantly reduced numbers of SMA ES
cells compared to control ES cells 5 days after differen-
tiation (C. Wu, D. Whye, W. Wang, unpublished data)
and why motor neurons are particularly sensitive to
SMN deficiency in SMA patients. Stress-induced cell
death is more pronounced in fibroblasts derived from
SMA patients compared to age-matched controls [68],
and regulation of SMN expression directly influences
cell survival [69-72]. Modulation of levels of down-
stream effectors of cell death such as pro-apoptotic Bax
and the antiapoptotic factor Bcl-xL in SMA mice directly
impacts the disease phenotype and lifespan of SMA
mice [73,74]. All these studies support the hypothesis
that SMN plays an active role in cell survival. The
recent groundbreaking discovery that human fibroblasts
can be reprogrammed into an ES cell-like state has sig-
nificantly advanced the field of stem cell and neurode-
generative disease research. Therefore, it will be of great
interest to determine if the similar pathways are aber-
rantly regulated in the induced pluripotent stem cells
derived from SMA fibroblasts.
Conclusion
We have derived SMN-deficient ES cells from a severe
transgenic SMA mouse which represent a cell-culture
model of SMA. Our work indicates that lower expres-
sion of SMN activates cellular stress pathways and
causes a dysregulation of energy metabolism, protein
degradation, and cytoskeleton stability.
Methods
Embryonic stem cell culture
HBG3 ES cells were derived from a HB9::GFP (mHB9-
Gfp1b) transgenic mouse as previously reported [31], and
control (SMN2+/+; Smn+/+) and SMA (SMN2+/+;
Smn-/-) murine ES cells were derived from a SMA trans-
genic mouse (FVB.Cg-Tg(SMN2)89Ahmb Smn1
tm1Msd/J)
[25] using similar techniques. All mice were obtained from
Jackson Laboratories, Bar Harbor, ME, USA. All proce-
dures involving animals for deriving ES cells were per-
formed in conformity with the guidelines of the National
Institutes of Health and were approved by the Johns-Hop-
kins University Institutional Animal Care and Use Com-
mittee (approved protocol number: MO06M240).
Figure 10 Up-regulation of p21 in SMN-deficient ES cells and
spinal cord tissues derived from SMA mice. Control (C) and SMA
(S) ES cells as described in 3A were processed for western blotting
using antibodies against p21 and p27. The same membrane was
stripped and re-probed with anti-ERK antibody for protein loading
control (A). Spinal cord tissues from three control (C) and three SMA
(S) mice were collected and lysates were prepared. Equal amount of
protein lysates were separated on a SDS-PAGE and transferred to a
membrane. The blot was probed with antibodies against p21 or
SMN. The same blot was stripped and re-probed with anti-ERK
antibody for protein loading control (B). Undiff. = undifferentiated
cells and Diff. = differentiated cells.
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Page 9 of 13Embryonic stem cells were expanded on feeder layers of
primary mouse embryonic fibroblasts (PMEF, hygro-resis-
tant, passage 3, PMEF-H; Millipore, Billerica, MA, USA)
in 100-mm tissue culture dishes. Cells were cultured with
ES cells growth medium containing DMEM supplemented
with 15% fetal bovine serum (FBS, Stem Cell Technolo-
gies, Vancouver, BC, Canada), 1% GlutaMax-I supplement,
1% MEM non-essential amino acids, 1% nucleosides, 0.1
mM b-mercaptoethanol, 1% penicillin/streptomycin, and 1
μl/ml murine leukemia inhibitor factor (Millipore). When-
ever possible, stem-cell grade reagents were used for ES
cell culture.
Differentiation of ES cells into motor neurons
Embryonic stem cells on fibroblast feeder layers were dis-
sociated with 0.25% trypsin/EDTA and plated onto 0.1%
gelatin-coated tissue culture flasks. Fibroblasts were
allowed to re-attach to the flask, and then the floating ES
cell population was collected. Approximately 2 × 10
6
cells were plated into 100-mm petri dishes containing 10
ml of neural differentiation priming medium containing
DMEM supplemented with 15% FBS, 1% MEM non-
essential amino acids, 1% GlutaMax-I supplement, 1%
penicillin/streptomycin, 1 mM monothio-glycerol, 50 ng/
ml Noggin (Invitrogen, Carlsbad, CA, USA), 20 ng/ml
bFGF (Invitrogen), and 20 ng/ml FGF-8 (Invitrogen) for
EB formation. Media were replaced daily. After two days,
aggregated EBs were re-suspended in motor neuron dif-
ferentiation medium (NITSf) containing basal medium A
supplemented with 10% knockout serum replacement
(Invitrogen), 1% N-2 supplement, 1% ITS-B supplement
(Stem Cell Technologies), 1% ascorbic acid, 1% penicil-
lin/streptomycin, 0.1 mM b-mercaptoethanol, 0.5% Glu-
taMax-I supplement, 30% D-glucose, 20 μg/ml heparin
(Sigma, St. Louis, MO, USA) and 50 μg/ml fibronectin
(Stem Cell Technologies) in the presence of 1 μMR A
(Sigma) and 1 μM SAG (Calbiochem, Gibbstown, NJ,
USA). Media were replaced daily. After 5 days of induc-
tion with RA and SAG, EBs were collected, washed with
phosphate-buffered saline (PBS), and dissociated in
Accumax (Millipore) following the manufacturer’s proto-
col. Cell aggregates were depleted from dissociated EBs
by filtering through a BD cell strainer. Single cells were
then suspended in NITSf medium supplemented with
10 ng/ml of each BDNF, GDNF, CNTF, and NT-3 and
plated at a concentration of 1 × 10
5 cells per well of
24 well plates that contained poly-DL-ornithine hydro-
bromide (Sigma)/laminin (Millipore)/matrigel- (BD
Bioscience, San Jose, CA, USA) coated coverslips.
Comparative two-dimensional SDS-polyacrylamide gel
electrophoresis and mass spectrometry analysis
Undifferentiated and differentiated control and SMA ES
cells were lysed in 30 mM Tris, pH 8.5 containing 7 M
urea, 2 M thiourea, and 4% CHAPS. Lysates were
cleared by centrifuging at 12,000 × g at 4ºC for 10 min.
A portion of each sample supernatant was pooled
together to create an internal standard. Individual sam-
ples were labeled with CyDye DIGE Fluor minimal
labeling dyes (GE Healthcare, Piscataway, NJ, USA) at a
ratio of 200 pmol Cydye per 50 μg protein according to
manufacturer’s protocols. For each experiment, two con-
trol and two SMA samples were labeled with Cy3, and
another two control and two SMA samples were labeled
with Cy5. This dye swap was performed to negate any
dye preference artifacts in analysis. The internal stan-
dard protein pool was labeled with Cy2. Equal portions
of control, SMA, and internal standard were mixed and
loaded onto IPG strips (BioRad, Hercules, CA, USA) via
rehydration in the presence of the same lysis buffer (see
above) containing 0.5% Pharmalyte 3-10 (BioRad). Sam-
ples from undifferentiated ES cells were run on pH 3-10
linear IPG strips, while differentiated samples were run
on pH 3-10 non-linear IPG strips. After isoelectric
focusing, IPG strips were equilibrated for 15 min with
75 mM Tris, pH 8.8, 6 M Urea, 30% Glycerol, 2% SDS,
and 65 mM DTT followed by 15 min with 75 mM Tris,
pH 8.8, 6 M Urea, 30% Glycerol, 2% SDS, and 135 mM
iodoacetamide (Sigma). The IPG strips were loaded onto
10% SDS-PAGE gels, and proteins were separated by
electrophoresis and imaged using a Typhoon Trio Scan-
ner (GE Healthcare). Changes in levels of individual pro-
tein spots were determined using Decyder 6.5 software
(GE Healthcare). Statistical significance of the change
was determined using a paired, two-tailed Student’s t-
test. Spots were ranked according to p-values. Spots
with a t-test p-value of less than 0.05 and an average
ratio greater than or less than 1.5 were picked and tryp-
sin digested.
Peptide identities were determined by mass spectro-
metry. Matrix-assisted laser desorption ionization time-
of-flight mass spectrometry (MALDI TOF MS) was car-
ried out on a 4800 MALDI TOF/TOF Analyzer (Applied
Biosystems, Atlanta, GA, USA). Peptide mass fingerprint
(PMF) spectra were obtained in positive ion reflector
mode with internal calibration for each sample. Four
peaks from each spectrum were selected and subjected
to further fragmentation for sequence information via
tandem MS (MS/MS) with default calibration. Using the
search program Mascot (v2.2, Matrix Sciences), PMF
and MS/MS spectra were submitted for database
searches with the following parameters: NCBInr data-
base, trypsin enzyme, 1 maximum missed cleavage, oxi-
dation of methionines, carbamidomethylation of
cysteines, 75 ppm precursor mass tolerance, and 0.3 Da
MS/MS fragment mass tolerance. Only protein matches
with a probability score below the significance threshold
(p < 0.05) were considered.
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Page 10 of 13Immunocytochemistry and western blot analysis
Immunocytochemistry and western blot analyses were
performed as previously described [68,75]. In brief, differ-
entiated ES cells were washed in PBS, fixed with 4% par-
aformaldehyde in PBS for 10 min, and permeabilized in
0.1% NP-40 in PBS for 15 min. After two washes with 1×
PBS, cells were blocked in 5% BSA in Tris-buffered saline
containing 0.05% Tween-20 (TBS-T) for 1 hr at room
temperature and then incubated overnight at 4°C with
mouse anti-Islet-1 (1:50, 39.4D5, Developmental Studies
Hybridoma Bank, Iowa City, IA, USA), goat anti-choline
acetyltransferase (1:200, Millipore), or chicken anti-neu-
rofilament (1:200, Millipore). After washing three times
with TBS-T, the cells were incubated with donkey anti-
mouse Texas Red, donkey anti-chicken Texas Red, or
donkey anti-goat DyLight 549. All secondary antibodies
were purchased from Jackson ImmunoResearch (West
Grove, PA, USA). Slides were mounted in Vectashield
containing DAPI (Vector Laboratories, Burlingame, CA,
USA).
For western blotting, spinal cord samples were col-
lected at P2-5 from the same colonies of transgenic
mice used to derive control and SMA ES cells (see
above). All procedures involving animals for collecting
spinal cord tissues were performed in conformity with
the guidelines of the National Institutes of Health and
were approved by the Nemours/Alfred I. duPont Hos-
pital for Children Institutional Animal Care and Use
Committee (approved protocol number: NBR-2008-
003). Prior to tissue harvesting, the genotype of SMA
pups were determined by standard PCR (Jackson
laboratories). Lysates from spinal cord tissues and ES
cells were prepared, protein concentrations were mea-
sured using the BCA assay, and western blot analyses
were performed as previously described [68,75]. In
brief, 50 μg of total protein lysates were resolved by
10% SDS-PAGE and transferred to nitrocellulose mem-
branes. The membranes were probed with the follow-
ing antibodies: neurofilament (1:500, Millipore), ChAT
(1:500, Millipore), Hb9 (1:10,000, Abcam, Cambridge,
MA, USA), SMN (1:1000, BD Biosciences), Gemin2
(2E17, 1:1000, Abcam), peroxiredoxin 6 (1:1000,
Abcam), lactate dehydrogenase (1:5000, Abcam), tropo-
myosin 1/3 (1:1000, Cell Signaling, Danvers, MA,
USA), p38, p-p38, JNK, p-JNK (1:1000, Cell Signaling),
p21 (1:500, Cell Signaling), p27 (1:2500, BD
Bioscience), TIA-1 (1:500, Santa Cruz, Santa Cruz, CA,
USA), and Erk (1:10,000, Santa Cruz). The blots were
then incubated with the appropriate secondary HRP-
conjugated antibodies, and proteins were detected
using enhanced chemiluminescence (GE Healthcare).
Signals were quantified, and ratios of proteins of inter-
est to Erk were calculated as previously described
[68,75]. Statistical analyses were determined using a
paired, two-tailed Student’s t-test (GraphPad Prism
s o f t w a r e ,L aJ o l l a ,C A ) .P - v a l u e sl e s st h a n0 . 0 5w e r e
considered to be statistically significant.
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